172 related articles for article (PubMed ID: 26004150)
1. The role of laquinimod in modulation of the immune response in relapsing-remitting multiple sclerosis: Lessons from gene expression signatures.
Zilkha-Falb R; Gurevich M; Hayardeny L; Achiron A
J Neuroimmunol; 2015 Jun; 283():11-6. PubMed ID: 26004150
[TBL] [Abstract][Full Text] [Related]
2. Laquinimod suppress antigen presentation in relapsing-remitting multiple sclerosis: in-vitro high-throughput gene expression study.
Gurevich M; Gritzman T; Orbach R; Tuller T; Feldman A; Achiron A
J Neuroimmunol; 2010 Apr; 221(1-2):87-94. PubMed ID: 20347159
[TBL] [Abstract][Full Text] [Related]
3. Modulation of dendritic cell properties by laquinimod as a mechanism for modulating multiple sclerosis.
Jolivel V; Luessi F; Masri J; Kraus SH; Hubo M; Poisa-Beiro L; Klebow S; Paterka M; Yogev N; Tumani H; Furlan R; Siffrin V; Jonuleit H; Zipp F; Waisman A
Brain; 2013 Apr; 136(Pt 4):1048-66. PubMed ID: 23518712
[TBL] [Abstract][Full Text] [Related]
4. Laquinimod (ABR-215062) for the treatment of relapsing multiple sclerosis.
Constantinescu SE; Constantinescu CS
Expert Rev Clin Pharmacol; 2016; 9(1):49-57. PubMed ID: 26536299
[TBL] [Abstract][Full Text] [Related]
5. Laquinimod, a new oral autoimmune modulator for the treatment of relapsing-remitting multiple sclerosis.
Tselis A
Curr Opin Investig Drugs; 2010 May; 11(5):577-85. PubMed ID: 20419604
[TBL] [Abstract][Full Text] [Related]
6. Laquinimod in multiple sclerosis.
Giacomini PS; Bar-Or A
Clin Immunol; 2012 Jan; 142(1):38-43. PubMed ID: 21450529
[TBL] [Abstract][Full Text] [Related]
7. Insight into the mechanism of laquinimod action.
Brück W; Wegner C
J Neurol Sci; 2011 Jul; 306(1-2):173-9. PubMed ID: 21429524
[TBL] [Abstract][Full Text] [Related]
8. Safety and in vivo immune assessment of escalating doses of oral laquinimod in patients with RRMS.
Ziemssen T; Tumani H; Sehr T; Thomas K; Paul F; Richter N; Samara E; Spiegelstein O; Sorani E; Bar-Ilan O; Mimrod D; Hayardeny L
J Neuroinflammation; 2017 Aug; 14(1):172. PubMed ID: 28859672
[TBL] [Abstract][Full Text] [Related]
9. Laquinimod in the treatment of relapsing remitting multiple sclerosis.
Hainke U; Thomas K; Ziemssen T
Expert Opin Drug Metab Toxicol; 2016 Jun; 12(6):701-9. PubMed ID: 27089834
[TBL] [Abstract][Full Text] [Related]
10. Laquinimod: a promising oral medication for the treatment of relapsing-remitting multiple sclerosis.
Thöne J; Gold R
Expert Opin Drug Metab Toxicol; 2011 Mar; 7(3):365-70. PubMed ID: 21306281
[TBL] [Abstract][Full Text] [Related]
11. Oral laquinimod therapy in relapsing multiple sclerosis.
Preiningerova J
Expert Opin Investig Drugs; 2009 Jul; 18(7):985-9. PubMed ID: 19527103
[TBL] [Abstract][Full Text] [Related]
12. Laquinimod efficacy in relapsing-remitting multiple sclerosis: how to understand why and if studies disagree.
Cutter GR; Knappertz V; Sasson N; Ladkani D
BMC Neurol; 2016 Sep; 16():176. PubMed ID: 27639853
[TBL] [Abstract][Full Text] [Related]
13. Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.
Comi G; Pulizzi A; Rovaris M; Abramsky O; Arbizu T; Boiko A; Gold R; Havrdova E; Komoly S; Selmaj K; Sharrack B; Filippi M;
Lancet; 2008 Jun; 371(9630):2085-92. PubMed ID: 18572078
[TBL] [Abstract][Full Text] [Related]
14. IFN-beta1b induces transient and variable gene expression in relapsing-remitting multiple sclerosis patients independent of neutralizing antibodies or changes in IFN receptor RNA expression.
Reder AT; Velichko S; Yamaguchi KD; Hamamcioglu K; Ku K; Beekman J; Wagner TC; Perez HD; Salamon H; Croze E
J Interferon Cytokine Res; 2008 May; 28(5):317-31. PubMed ID: 18547162
[TBL] [Abstract][Full Text] [Related]
15. Placebo-controlled trial of oral laquinimod for multiple sclerosis.
Comi G; Jeffery D; Kappos L; Montalban X; Boyko A; Rocca MA; Filippi M;
N Engl J Med; 2012 Mar; 366(11):1000-9. PubMed ID: 22417253
[TBL] [Abstract][Full Text] [Related]
16. Laquinimod dampens IL-1β signaling and Th17-polarizing capacity of monocytes in patients with MS.
Engel S; Jolivel V; Kraus SH; Zayoud M; Rosenfeld K; Tumani H; Furlan R; Kurschus FC; Waisman A; Luessi F
Neurol Neuroimmunol Neuroinflamm; 2021 Jan; 8(1):. PubMed ID: 33203651
[TBL] [Abstract][Full Text] [Related]
17. Interferon beta-1a induces tumor necrosis factor receptor 1 but decreases tumor necrosis factor receptor 2 leukocyte mRNA levels in relapsing-remitting multiple sclerosis.
Reuss R; Pohle S; Retzlaff K; Hemberger J; Oschmann P
Neuroimmunomodulation; 2009; 16(3):171-6. PubMed ID: 19246939
[TBL] [Abstract][Full Text] [Related]
18. Assessment of changes in immune measures of multiple sclerosis patients treated with laquinimod.
Lund BT; Kelland EE; Hayardeny L; Barilan O; Gilmore W; Weiner LP
J Neuroimmunol; 2013 Oct; 263(1-2):108-15. PubMed ID: 23920036
[TBL] [Abstract][Full Text] [Related]
19. Gene expression changes in peripheral blood mononuclear cells from multiple sclerosis patients undergoing beta-interferon therapy.
Singh MK; Scott TF; LaFramboise WA; Hu FZ; Post JC; Ehrlich GD
J Neurol Sci; 2007 Jul; 258(1-2):52-9. PubMed ID: 17467740
[TBL] [Abstract][Full Text] [Related]
20. Oral laquinimod treatment in multiple sclerosis.
Fernández O
Neurologia; 2011 Mar; 26(2):111-7. PubMed ID: 21163185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
